Adalimumab
Concept
Vocabulary Service
Overview
subject area of
-
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis Academic Article
-
Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet Academic Article
-
Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies Academic Article
-
Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis Academic Article
-
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis Academic Article
-
An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. Academic Article
-
Anti-TNFα therapy in immune-mediated subfertility: State of the art Academic Article
-
Bell's palsy in a patient receiving adalimumab for Crohn's disease Academic Article
-
Biologic survival. Academic Article
-
COMMENTARY: Should Anti-TNF-α Therapy be Offered to Patients with Infertility and Recurrent Spontaneous Abortion?* Academic Article
-
Canada's Study of Adherence Outcomes in Patients Receiving Adalimumab: 3-year Results From the COMPANION Study Academic Article
-
Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Academic Article
-
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease Conference Paper
-
Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti‐tumor necrosis factor experienced Crohn's disease patients: A propensity‐score matched cohort analysis Academic Article
-
Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs Academic Article
-
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis Academic Article
-
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab Academic Article
-
Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn’s Disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn’s DiseaSe (ACCESS) Trial Academic Article
-
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis Academic Article
-
Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab Academic Article
-
Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn’s disease patients Academic Article
-
Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease Academic Article
-
Immunotherapies in Dermatologic Disorders Academic Article
-
Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study Academic Article
-
Impact of the Adalimumab Patient Support Program's Care Coach Calls on Persistence and Adherence in Canada: An Observational Retrospective Cohort Study Academic Article
-
Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate Academic Article
-
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease Academic Article
-
Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease - should one consider disease location? Authors’ reply Academic Article
-
Long-Term Outcomes of Early vs Delayed Responders to Vedolizumab and Adalimumab: A Post Hoc Analysis of the VARSITY Study Academic Article
-
Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease Academic Article
-
Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Academic Article
-
Patient outcomes after anti TNF-α drugs for Crohn’s disease Academic Article
-
Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics Academic Article
-
Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database Academic Article
-
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease Academic Article
-
Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study Academic Article
-
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial Academic Article
-
The economics of adalimumab for ulcerative colitis Academic Article
-
The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-α naïve Crohn's disease Academic Article
-
Treatment of severe facial psoriasis with adalimumab. Academic Article
-
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial Academic Article
-
Vedolizumab and Adalimumab in Biologic-Naïve Ulcerative Colitis: Comparison of Patient-Level Clinical Trial Data and VARSITY for Week 6 Clinical Remission Academic Article
-
Week 2 Adalimumab Levels Predict Short-term Clinical Remission in Patients With Inflammatory Bowel Disease Academic Article